HCC treatment options have considerably improved over the last few years, ranging from surgical resection, loco-regional approaches (thermal ablation and transarterial chemoembolization), to liver transplantation or drugs, such as sorafenib or lenvatinib, for an advanced disease, and immunotherapeutic treatment with anti-PD-L1 and anti-VEGF [29]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.